Click on title to access full-text post in new browser window.

Posted in 2009:

• What Techniques are Used by Pharma to Monitor Adve...
• Who Should Be Responsible for Submitting Adverse E...
• How is Adverse Event Information from Social Media...
• Challenges Handling Adverse Events Found on SM Sit...
• Uncertainties Regarding Reporting Adverse Events F...
• Are J&J Agents Trolling for Adverse Events on the ...
• Twitter and Drug Safety: A Paramount Concern
• FDA Cannot Track Its Own Review of Adverse Event R...
• Will Latisse Turn Brooke Shields' Blue Eyes Brown?
• Unintended Consequences of FDA Warnings: Lilly-funded Antidepressant Case Study
• Pristiq DTC Campaign Challenged to Concisely Communicate Risk
• Arnold Friede Blasts FDA's Right to Define "Reasonable Man" Without External Input
• Communicating Risk in Online Drug Ads: Reading the Tea Leaves in Recent FDA Draft Guidance
• Drug Fact Box: It All Depends on What You Mean by "Fact"
• Let's Focus on Effectiveness, Not Dollars Spent as a Measure of DTC Success

Posted in 2008:

• Want to See Adverse Events of Drugs You are Taking? Try This Site
• New FDA Data: Adverse Event Reporting Increases Dramatically
• Despite FDA Warning Letter, YAZ Web Site Still Connects YAZ with Treatment of Acne!
• Marketing Causes Death: the Link Between Black Friday and Black Boxes
• Microsoft Claims Web Searches Bad for Your Health?
• "Making A Killing:" Scientology Video Blasts the Pyschiatry-Drug Industry-FDA Complex!
• Scare Balance or Scare Tactics? A Weak Case Against More DTC Risk Information
• FDA Intern Learns All About the "Affect Misattribution Procedure"
• How Risky are Rx Drugs?
• Take alli - I dare you!
• Consumers Jazzed by Adverse Events!
• Chantix "Roundtable" Apparently Not Round and Not a Table
• Trains, Planes, School Vans: Unsafe for Chantix Users
• Pfizer Invites This Blogger to Chantix Media Roundtable Discussion
• Caucuses, Coffee Shop Focus Groups, and Cholesterol
• The Statin Lottery: Number Needed to Treat Statistic

Posted in 2007:

• Mevacor - STRIKE THREE! Yer Outta Here!
• Lilly, Sweden, Bribes and Conspiracy Theories
• Merck to Vioxx Plaintiffs: Settle or Else!
• What the US FDA Could Learn from China's FDA
• Another Award for Rozerem! This one...not so good.
• Statins and Heart Disease: Look Behind the Curtain
• Gardasil: Is the Risk of Being "One Less" Worth It?
• Lilly Cymbalta Marketers are NOT Practicing What Lilly Executives Preach!
• DTC Here to Stay; Pet Turtles Too!
• Risk-First DTC: A Tactic to Overcome Resistance
• An Innovative System for Communicating Drug Risks to Patients
• FDA Considers Color Code for Food Labels, But Not for Drug Labels
• FDA at a Mall Near You: The Manchurian Connection
• FDA's Chang and Eng: Benefit vs. Risk
• Can an In-home Electronic Pillbox Solve Our Medication Error Problem?
• FDA: Zimulti Non-Acomplia!
• Avandia Hearing Soap Opera: Ethics, Demagogy, Sensationalism, and Threats by GSK
• Avandia Hearing Begins with Slurs Against NEJM and Majority Members
• Pharma Hires Charlatans for Research & Marketing!
• Avandia: Enough Blame to Go Around
• GSK May "Step Into the [DTC] Void" to Defend Avandia
• Temple vs. Nissen: Blood Rematch
• Myth #1: High U.S. Drug Prices Guarantee Us First Shot at New Drugs
• Imagine There's No DTC. I Wonder If You Can.
• DUI: Dispensing Under the Influence
• This is Your Inner Ear on Drugs!
• Botox Banality Not a Boon for TV Sitcoms
• Celebrex Ad: Let's Dive Deeper
• The New Celebrex TV Ad: What Did You Learn?
• Acomplia Not for the Gun Totting Bikini Crowd
• von Eschenbach & Gonzales: Two Birds in the Same Bush
• Drug Safety - A Mere Asterisk to the FDA

Posted in 2006:

For access to the following posts, please use the Monthly Archive.

• torcetrapib: "$800 Million" Failure but Kindler Safe
• Pfizer's torcetrapib: Who Knew What, When?
• Off-Label Confusion
• Lame-Duck Senate Roasts Eschenbach Turkey!
• Pay Per DTC Ad View Update
• Merck Management Is "Exonerated"
• What's In Store from Congress?
• Marketing 101: Newer is Better
• Print DTC, PhRMA Guidelines, and Balance
• Imprecise DTC Benefit Messages
• Welcome Back Vioxx, Welcome Back
• Apres IOM, le Deluge!
• IOM Report Calls for DTC Moratorium
• Health Literacy - Words Fail to Tell the Story
• Caduet, Smaduet! Add some wood to the fire!
• WLF: A No-Risk Ad is a Good Ad
• Accountability: Imported vs. Domestic
• We Were Hoodwinked!
• PhRMA Intern Tackles Terrorists!
• Generics: Physicians Less Informed than Consumers!
• FDA Paralyzed: Who Will Protect Us?
• Drug Risks: Consumers Less Concerned than Docs
• FDA Gets a "C" from the Public
• Pfizer Imitating Art or Vice Versa?
• Celsius 3014: Ketek, Drug Safety, & Bioterrorism
• Spinning Bad News about FDA & Drug Safety
• FDA Coming to a Mall Near You?
• DTC without Risk Revisited
• Merck Misled FDA According to NJ Jury
• DTC without the Risk

Posted in 2005:
For access to the following posts, please use the Monthly Archive.

• Marketing "Acceptable Risk"
• PhRMA's Terrorist Plot
• Labeling / TV DTC Revisited
• HELP WANTED: Director of Drug Safety
• Future of Drug Print Ads
• Terror Politics vs Drug Importation
• Proposal for a Drug Risk Advisory System
• FDA Drug Watch Site Guidelines
• "Bioshield" Boondoggle
• Drug Safety: A Matter of Trust!
• FDA Advisory Panels: Elephants in the Room
• Canada: Mad Cows Yes, Drugs No!
• Can Drug Ads Communicate Risk?
• Merck's Hand in the Cookie Jar
• Vioxx Hex or Hoax?
• Merck Changes Tactics, Lawyers Too
• Merck science "like wah, wah, wah"
• Jury as Focus Group
• Merck Found Negligent!
• Patients Come First?
• Get a Load of Those Gams!
• Cox-2's (and Pfizer?) on Slippery Slope
• Vioxx Redux
• Pharmaceutical PR: Fool Me Once, Fool Me Twice
• Cox-2's Die Hard: With a Vengeance
• Who Should Pay for Merck's Obstructionism?